ad image

HER2-Positive Cancers

1 / 1
Boehringer Ingelheim Pharmaceuticals, Inc.
FDA

Boehringer's Zongertinib ReceivesFDA Priority Review for the Treatment of HER2 (ERBB2)- NSCLC

Boehringer Ingelheim Pharmaceuticals, Inc.

PR-02-25-NI-21Feb 20, 2025
EXUMA Biotechnology
Clinical Trials

EXUMA Biotech Announces Phase 1 Results for its Autologous HER2 Directed CAR-T Product at ASCO GI 2025

EXUMA Biotechnology

PR-01-25-NI-26Feb 11, 2025
Glenmark Pharmaceuticals
Agreement

Glenmark Pharmaceuticals and Harbour BioMed Sign Agreement for Greater China to Develop GBR 1302, a First-in-Class Bispecific Antibody for Treatment of HER2-Positive Cancers

Glenmark Pharmaceuticals

PR-M08-18-NI-050Aug 13, 2018
1 / 1